Author:
Wegscheider Christoph,Ferincz Vera,Schöls Karin,Maieron Andreas
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Hellmich B, Agueda A, Monti S, Buttgereit F, De Boysson H, Brouwer E et al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19–130
2. Martínez-Taboada VM, López-Hoyos M, Narvaez J, Muñoz-Cacho P (2014) Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev 13(8):788–794
3. Lee MS, Smith SD, Galor A, Hoffman GS (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54(10):3306–3309
4. Narváez FJG, Bernad B, Gómez-Vaquero C, García-Gómez C, Roig-Vilaseca D, Juanola X et al (2008) Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 26(3 Suppl 49):S57–S62
5. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296–1304